Internet "Do not track" efforts could dash health data collection

Share this article:
The White House wants a national “Do not track” policy – a digital version of the “Do not call” registry – and that's making marketing and advertising policy hands nervous.

In Senate testimony yesterday, a Commerce Department official said the administration wants a "privacy bill of rights" for Internet users.

Pharmas, in particular, need to pay attention, said Coalition for Healthcare Communication executive director John Kamp, who worries that medical search and other online data could be subject to particularly stringent restrictions.

The Center for Digital Democracy, US PIRG and other groups have called for “clear consumer protection safeguards” for online health information. In a recent submission (.pdf) to the Federal Trade Commission, they wrote: “The focus on consumer protection and health/pharma marketing has traditionally been to ensure adequate risk information on drug side effects and contraindications for use. But the emergence of powerful new digital marketing techniques designed to influence consumer behavior around health conditions and medications requires a new approach to informing and protecting the public.”

Kamp's fear is that instead of an opt-out option, medical and health-related data could be subjected to an opt-in rule requiring viewers to essentially volunteer their data before marketers could collect it.

The newest editions of the Internet Explorer and Mozilla Firefox browsers will allow surfers to shun tracking, though these programs allow users different degrees of opacity. The Interactive Advertising Bureau has proposed a self-regulatory program making use of an “Advertising option icon” to alert surfers to behavioral advertising. The FTC has weighed requiring a “Do not track” browser button, and legislation has been introduced in Congress that would do just that.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...